The combined effect of MTHFR C677T and A1298C polymorphisms on the risk of digestive system cancer among a hypertensive population.

MTHFR polymorphisms A1298C C677T Case–control study Digestive system cancer

Journal

Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142

Informations de publication

Date de publication:
02 Apr 2024
Historique:
received: 27 06 2023
accepted: 29 03 2024
medline: 3 4 2024
pubmed: 3 4 2024
entrez: 2 4 2024
Statut: epublish

Résumé

The enzyme methylenetetrahydrofolate reductase (MTHFR) plays a crucial role in directing folate species towards nucleotide synthesis or DNA methylation. The MTHFR polymorphisms C677T and A1298C have been linked to cancer susceptibility, but the evidence supporting this association has been equivocal. To investigate the individual and joint associations between MTHFR C677T, A1298C, and digestive system cancer in a Chinese hypertensive population, we conducted a population-based case-control study involving 751 digestive system cancer cases and one-to-one matched controls from the China H-type Hypertension Registry Study (CHHRS). We utilized the conditional logistic regression model to evaluate multivariate odds ratios (ORs) and 95% confidence intervals (CIs) of digestive system cancer. The analysis revealed a significantly lower risk of digestive system cancer in individuals with the CT genotype (adjusted OR: 0.71; 95% CI 0.52, 0.97; P = 0.034) and TT genotype (adjusted OR: 0.57; 95% CI 0.40, 0.82; P = 0.003; P for trend = 0.003) compared to those with the 677CC genotype. Although A1298C did not show a measurable association with digestive system cancer risk, further stratification of 677CT genotype carriers by A1298C homozygotes (AA) and heterozygotes (AC) revealed a distinct trend within these subgroups. These findings indicate a potential protective effect against digestive system cancer associated with the T allele of MTHFR C677T. Moreover, we observed that the presence of different combinations of MTHFR polymorphisms may contribute to varying susceptibilities to digestive system cancer.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
The enzyme methylenetetrahydrofolate reductase (MTHFR) plays a crucial role in directing folate species towards nucleotide synthesis or DNA methylation. The MTHFR polymorphisms C677T and A1298C have been linked to cancer susceptibility, but the evidence supporting this association has been equivocal. To investigate the individual and joint associations between MTHFR C677T, A1298C, and digestive system cancer in a Chinese hypertensive population, we conducted a population-based case-control study involving 751 digestive system cancer cases and one-to-one matched controls from the China H-type Hypertension Registry Study (CHHRS).
METHODS METHODS
We utilized the conditional logistic regression model to evaluate multivariate odds ratios (ORs) and 95% confidence intervals (CIs) of digestive system cancer.
RESULTS RESULTS
The analysis revealed a significantly lower risk of digestive system cancer in individuals with the CT genotype (adjusted OR: 0.71; 95% CI 0.52, 0.97; P = 0.034) and TT genotype (adjusted OR: 0.57; 95% CI 0.40, 0.82; P = 0.003; P for trend = 0.003) compared to those with the 677CC genotype. Although A1298C did not show a measurable association with digestive system cancer risk, further stratification of 677CT genotype carriers by A1298C homozygotes (AA) and heterozygotes (AC) revealed a distinct trend within these subgroups.
CONCLUSION CONCLUSIONS
These findings indicate a potential protective effect against digestive system cancer associated with the T allele of MTHFR C677T. Moreover, we observed that the presence of different combinations of MTHFR polymorphisms may contribute to varying susceptibilities to digestive system cancer.

Identifiants

DOI: 10.1007/s12672-024-00960-y PMID: 38565713
pubmed: 38565713
doi: 10.1007/s12672-024-00960-y
pii: 10.1007/s12672-024-00960-y
doi:

Types de publication

Journal Article

Langues

eng

Pagination

97

Subventions

Organisme : the National Key Research and Development Program
ID : 2022YFC2009600
Organisme : the National Key Research and Development Program
ID : 2022YFC2009601
Organisme : the Department of Science and Technology of Guangdong Province, and the Development and Reform Commission of Shenzhen Municipality
ID : XMHT20220104055
Organisme : National Key Research and Development Program of China
ID : 2018ZX09739010
Organisme : National Key Research and Development Program of China
ID : 2018ZX09301034003
Organisme : the Department of Science and Technology of Guangdong Province, Guangdong Key Laboratory of H-type Hypertension and Stroke Precision Prevention Research and Development Enterprise
ID : 2020B121202010
Organisme : Science, Technology and Innovation Committee of Shenzhen
ID : JSGG20180703155802047
Organisme : Science, Technology and Innovation Committee of Shenzhen
ID : JSGG20201103153807021
Organisme : Science, Technology and Innovation Committee of Shenzhen
ID : KCXFZ20211020163801002

Informations de copyright

© 2024. The Author(s).

Références

Matsuo K, Hamajima N, Suzuki R, Ogura M, Kagami Y, Taji H, et al. Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma. Am J Hematol. 2004;77(4):351–7.
pubmed: 15551285 doi: 10.1002/ajh.20215
Chou Y, Wu M, Yu J, Lee M, Yang T, Shih H, et al. Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: a case–control study in Taiwan. Carcinog. 2006;27(11):2295–300.
doi: 10.1093/carcin/bgl108
Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37(11):1012–27.
pubmed: 34120771 doi: 10.1016/j.tig.2021.05.002
Saghafinia S, Mina M, Riggi N, Hanahan D, Ciriello G. Pan-cancer landscape of aberrant DNA methylation across human tumors. Cell Rep. 2018;25(4):1066-1080.e8.
pubmed: 30355485 doi: 10.1016/j.celrep.2018.09.082
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–3.
pubmed: 7647779 doi: 10.1038/ng0595-111
Kim Y. Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem. 1999;10:66–88.
pubmed: 15539274 doi: 10.1016/S0955-2863(98)00074-6
Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001;22(4):195–201.
pubmed: 11282420 doi: 10.1016/S0165-6147(00)01675-8
Murakami S, Matsubara N, Saitoh M, Miyakawa S, Shoji M, Kubo T. The Relation between plasma homocysteine concentration and methylenetetrahydrofolate reductase gene polymorphism in pregnant women. J Obstet Gynaecol Res. 2001;27(6):349–52.
pubmed: 11794822 doi: 10.1111/j.1447-0756.2001.tb01284.x
Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet. 2011;378(9791):584–94.
pubmed: 21803414 pmcid: 3156981 doi: 10.1016/S0140-6736(11)60872-6
Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease. JAMA. 2002;288:2023–31.
pubmed: 12387655 doi: 10.1001/jama.288.16.2023
Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000;151(9):862–77.
pubmed: 10791559 doi: 10.1093/oxfordjournals.aje.a010290
Huang X, Qin X, Yang W, Liu L, Jiang C, Zhang X, et al. MTHFR gene and serum folate interaction on serum homocysteine lowering: prospect for precision folic acid treatment. Arterioscler Thromb Vasc Biol. 2018;38(3):679–85.
pubmed: 29371246 doi: 10.1161/ATVBAHA.117.310211
van der Put NM, Gabreëls F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet. 1998;62(5):1044–51.
pubmed: 9545395 pmcid: 1377082 doi: 10.1086/301825
Gong Z, Yao S, Zirpoli G, David Cheng TY, Roberts M, Khoury T, et al. Genetic variants in one-carbon metabolism genes and breast cancer risk in European American and African American women. Int J Cancer. 2015;137(3):666–77.
pubmed: 25598430 pmcid: 4437886 doi: 10.1002/ijc.29434
Li Q, Lan Q, Zhang Y, Bassig BA, Holford TR, Leaderer B, Boyle P, et al. Role of one-carbon metabolizing pathway genes and gene–nutrient interaction in the risk of non-Hodgkin lymphoma. Cancer Causes Control. 2013;24(10):1875–84.
pubmed: 23913011 pmcid: 3951097 doi: 10.1007/s10552-013-0264-3
Gong JM, Shen Y, Shan WW, He YX. The association between MTHFR polymorphism and cervical cancer. Sci Rep. 2018;8(1):7244.
pubmed: 29740106 pmcid: 5940696 doi: 10.1038/s41598-018-25726-9
Nisevic I, Dinic J, Nikolic A, Djordjevic V, Lukic S, Ugljesic M, et al. MTHFR C677T polymorphism in chronic pancreatitis and pancreatic adenocarcinoma. Cell Biochem Funct. 2008;26(6):659–63.
pubmed: 18636416 doi: 10.1002/cbf.1487
Shen H, Xu Y, Zheng Y, Qian Y, Yu R, Qin Y, et al. Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of gastric cancer in a Chinese population: a case-control study. Int J Cancer. 2001;95:332–6.
pubmed: 11494235
Sheng X, Zhang Y, Zhao E, Lu S, Zheng X, Ge H, et al. MTHFR C677T polymorphism contributes to colorectal cancer susceptibility: evidence from 61 case–control studies. Mol Biol Rep. 2012;39(10):9669–79.
pubmed: 22729883 doi: 10.1007/s11033-012-1832-4
Yang Z, Zhang X, Liu H, Hao Y, Zhao C. MTHFR C677T polymorphism and colorectal cancer risk in Asians: a meta-analysis of 21 studies. Asian Pac J Cancer Prev. 2012;13(4):1203–8.
pubmed: 22799306 doi: 10.7314/APJCP.2012.13.4.1203
Wei Y, Xu B, He Q, Chen P, Zhang Q, Zhang X, Yuan H, Duan Y, Wang Z, Zhou Z, Liu L. Serum total folate, 5-methyltetrahydrofolate and Vitamin B12 concentrations on incident risk of lung cancer. Int J Cancer. 2023;152(6):1095–106.
pubmed: 36184907 doi: 10.1002/ijc.34307
Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313(13):1325–35.
pubmed: 25771069 doi: 10.1001/jama.2015.2274
Marchand LL, Wilkens LR, Kolonel LN, Henderson BE. The MTHFR C677T polymorphism and colorectal cancer the multiethnic cohort study. Cancer Epidemiol Biomark Prev. 2005;14(4):1198–203.
doi: 10.1158/1055-9965.EPI-04-0840
Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 1997;57(6):1098–102.
pubmed: 9067278
Hubner RA, Houlston RS. MTHFR C677T and colorectal cancer risk: a meta-analysis of 25 populations. Int J Cancer. 2006;120(5):1027–35.
doi: 10.1002/ijc.22440
Yin G, Kono S, Toyomura K, Hagiwara T, Nagano J, Mizoue T, et al. MTHFR C677T and A1298C polymorphisms and colorectal cancer: The Fukuoka colorectal cancer study. Cancer Sci. 2004;95(11):908–13.
pubmed: 15546509 doi: 10.1111/j.1349-7006.2004.tb02201.x
Tong N, Fang Y, Li J, Wang M, Lu Q, Wang S, et al. Methylenetetrahydrofolate reductase polymorphisms, serum methylenetetrahydrofolate reductase levels, and risk of childhood acute lymphoblastic leukemia in a Chinese population. Cancer Sci. 2010;101(3):782–6.
pubmed: 20002681 doi: 10.1111/j.1349-7006.2009.01429.x
Yan J, Yin M, Dreyer ZE, Scheurer ME, Kamdar K, Wei Q, et al. A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children. Pediatr Blood Cancer. 2012;58(4):513–8.
pubmed: 21495160 doi: 10.1002/pbc.23137
Sailasree R, Nalinakumari KR, Sebastian P, Kannan S. Influence of methylenetetrahydrofolate reductase polymorphisms in oral cancer patients. J Oral Pathol Med. 2011;40(1):61–6.
pubmed: 20923444 doi: 10.1111/j.1600-0714.2010.00943.x
Safarinejad MR, Shafiei N, Safarinejad S. Relationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: a case–control study. Prostate. 2010;70(15):1645–57.
pubmed: 20564317 doi: 10.1002/pros.21200
Zhong S, Yang J, Liu K, Jiao BH, Chang Z. Quantitative assessment of the association between MTHFR C677T polymorphism and colorectal cancer risk in East Asians. Tumor Biol. 2012;33(6):2041–51.
doi: 10.1007/s13277-012-0463-7
Graziano F, Kawakami K, Ruzzo A, Watanabe G, Santini D, Pizzagalli F, et al. Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. Int J Cancer. 2006;118(3):628–32.
pubmed: 16094648 doi: 10.1002/ijc.21397
Lacasaña-Navarro M, Galván-Portillo M, Chen J, López-Cervantes M, López-Carrillo L. Methylenetetrahydrofolate reductase 677C >T polymorphism and gastric cancer susceptibility in Mexico. Eur J Cancer. 2006;42(4):528–33.
pubmed: 16359859 doi: 10.1016/j.ejca.2005.10.020
Shannon B, Gnanasampanthan S, Beilby J, Iacopetta B. A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut. 2002;50:520–4.
pubmed: 11889073 pmcid: 1773174 doi: 10.1136/gut.50.4.520
Derwinger K, Wettergren Y, Odin E, Carlsson G, Gustavsson B. A study of the MTHFR gene polymorphism C677T in colorectal cancer. Clin Colorectal Cancer. 2009;8(1):43–8.
pubmed: 19203896 doi: 10.3816/CCC.2009.n.007
Kim JK, Kim S, Han JH, Kim HJ, Chong SY, Hong SP, et al. Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of stomach cancer in a Korean population. Anticancer Res. 2005;25:2249–52.
pubmed: 16158971
Vollset SE, Igland J, Jenab M, Fredriksen A, Meyer K, Eussen S, et al. The association of gastric cancer risk with plasma folate, cobalamin, and methylenetetrahydrofolate reductase polymorphisms in the european prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev. 2007;16(11):2416–24.
doi: 10.1158/1055-9965.EPI-07-0256
Suzuki T, Matsuo K, Hasegawa Y, Hiraki A, Wakai K, Hirose K, et al. One-carbon metabolism-related gene polymorphisms and risk of head and neck squamous cell carcinoma: case–control study. Cancer Sci. 2007;98(9):1439–46.
pubmed: 17596206 doi: 10.1111/j.1349-7006.2007.00533.x
Hekim N, Ergen A, Yaylım I, Yılmaz H, Zeybek Ü, Öztürk O, İsbir T. No association between methylenetetrahydrofolate reductase C677T polymorphism and breast cancer. Cell Biochem Funct. 2007;1:115–7.
doi: 10.1002/cbf.1274
Kim Y. Methylenetetrahydrofolate reductase polymorphisms, folate, and cancer risk a paradigm of gene-nutrient interactions in carcinogenesis. Nutr Rev. 2000;58(7):205–9.
pubmed: 10941256 doi: 10.1111/j.1753-4887.2000.tb01863.x
Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res. 1996;56:4862–4.
pubmed: 8895734
Dong X, Wu J, Liang P, Li J, Yuan L, Liu X. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer: a meta-analysis. Arch Med Res. 2010;41(2):125–33.
pubmed: 20470942 doi: 10.1016/j.arcmed.2010.01.001
Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64:169–72.
pubmed: 9719624 doi: 10.1006/mgme.1998.2714
Blount BC, Mack MM, Wehr CM, Macgregor JT, Hiatt RA, Wang G, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA. 1997;94:3290–5.
pubmed: 9096386 pmcid: 20362 doi: 10.1073/pnas.94.7.3290
Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA. 1998;95:13217–20.
pubmed: 9789068 pmcid: 23763 doi: 10.1073/pnas.95.22.13217
Quinlivan EP, Davis SR, Shelnutt KP, Henderson GN, Ghandour H, Shane B, et al. Methylenetetrahydrofolate reductase 677C→T polymorphism and folate status affect one-carbon incorporation into human DNA deoxynucleosides. J Nutr. 2005;135(3):389–96.
pubmed: 15735068 doi: 10.1093/jn/135.3.389
Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. JNCI J Natl Cancer Inst. 2004;96(2):134–44.
pubmed: 14734703 doi: 10.1093/jnci/djh015
Yang B, Fan S, Zhi X, Xia R, Wang Y, Zheng Q, et al. Geographical and ethnic distribution of MTHFR gene polymorphisms and their associations with diseases among Chinese population. Clin Genet. 2017;92(3):243–58.
pubmed: 27888505 doi: 10.1111/cge.12929
Meng Y, Liu X, Ma K, Zhang L, Lu M, Zhao M, et al. Association of MTHFR C677T polymorphism and type 2 diabetes mellitus (T2DM) susceptibility. Mol Genet Genom Med. 2019;7(12): e1020.
doi: 10.1002/mgg3.1020
Qian X, Lu Z, Tan M, Liu H, Lu D. A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur J Hum Genet. 2007;15(12):1239–45.
pubmed: 17726486 doi: 10.1038/sj.ejhg.5201914
Brattströma L, Zhang Y, Hurtig M, Refsum H, Stensson S, Fransson L, et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis. 1998;141:315–9.
doi: 10.1016/S0021-9150(98)00154-3

Auteurs

Qiangqiang He (Q)

Shenzhen International Graduate School, Tsinghua University, University Town of Shenzhen, No. 2279, Lishui Road. Nanshan District, Shenzhen, 518055, Guangdong, China.
Shenzhen Evergreen Medical Institute, Shenzhen, 518057, Guangdong, China.

Yaping Wei (Y)

College of Public Health, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.

Hehao Zhu (H)

School of Science, China Pharmaceutical University, Nanjing, 211198, Jiangsu, China.

Qiongyue Liang (Q)

State Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, 211198, Jiangsu, China.

Ping Chen (P)

College of Pharmacy, Jinan University, Guangzhou, 510632, Guangdong, China.
Inspection and Testing Center, Key Laboratory of Cancer FSMP for State Market Regulation, Shenzhen, 518057, China.

Shuqun Li (S)

Department of Gastrointestinal Surgery/Clinical Nutrition, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, 100038, China.

Yun Song (Y)

Shenzhen Evergreen Medical Institute, Shenzhen, 518057, Guangdong, China.

Lishun Liu (L)

Shenzhen International Graduate School, Tsinghua University, University Town of Shenzhen, No. 2279, Lishui Road. Nanshan District, Shenzhen, 518055, Guangdong, China.
Shenzhen Evergreen Medical Institute, Shenzhen, 518057, Guangdong, China.
Guangdong Key Laboratory of H-Type Hypertension and Stroke Precision Prevention Research and Development Enterprise, Shenzhen, 518057, China.

Binyan Wang (B)

Shenzhen Evergreen Medical Institute, Shenzhen, 518057, Guangdong, China.
Institute of Biomedicine, Anhui Medical University, Hefei, 230032, Anhui, China.

Xiping Xu (X)

National Clinical Research Center for Kidney Disease, State Key Laboratory for Organ Failure Research, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou Regenerative Medicine and Health, Guangdong Laboratory, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.

Yuhan Dong (Y)

Shenzhen International Graduate School, Tsinghua University, University Town of Shenzhen, No. 2279, Lishui Road. Nanshan District, Shenzhen, 518055, Guangdong, China. dongyuhan@sz.tsinghua.edu.cn.

Classifications MeSH